Screening colorectal cancer associated autoantigens through multi-omics analysis and diagnostic performance evaluation of corresponding autoantibodies

Table 2 Diagnostic performance of the 12 candidate TAAbs

Data	TAAbs	AUC (95%CI)	Sen (%)	Spe (%)	+LR	-LR	YI	P
Training Set	Anti-HMGA1	0.52(0.46–0.57)	10.00	94.29	1.75	0.95	0.04	0.587
	Anti-NPM1	0.50(0.45–0.56)	12.38	90.48	1.30	0.97	0.03	0.944
	Anti-EIF1AX	0.54(0.48–0.59)	20.48	85.71	1.43	0.93	0.06	0.208
	Anti-CKS1B	0.62(0.57–0.67)	29.05	88.57	2.54	0.80	0.18	< 0.001
	Anti-HSP90AB1	0.54(0.49–0.60)	30.95	85.71	2.17	0.81	0.17	0.125
	Anti-ACTG1	0.59(0.54–0.65)	24.29	88.57	2.12	0.85	0.13	< 0.001
	Anti-S100A11	0.64(0.58–0.69)	36.67	85.71	2.57	0.74	0.22	< 0.001
	Anti-maspin	0.58(0.52–0.63)	20.48	85.24	1.39	0.93	0.06	< 0.001
	Anti-ANXA3	0.62(0.57–0.67)	33.33	86.19	2.41	0.77	0.20	< 0.001
	Anti-eEF2	0.60(0.54–0.65)	22.86	94.29	4.00	0.82	0.17	< 0.001
	Anti-P4HB	0.52(0.47–0.58)	15.71	97.62	6.60	0.86	0.13	0.416
	Anti-HKDC1	0.52(0.46–0.57)	5.24	96.19	1.38	0.99	0.01	0.544
Test Set	Anti-CKS1B	0.67(0.59–0.75)	34.44	88.89	3.10	0.74	0.23	< 0.001
	Anti-ACTG1	0.53(0.45–0.62)	22.22	86.67	1.67	0.90	0.09	0.439
	Anti-S100A11	0.65(0.57–0.73)	37.78	88.89	3.40	0.70	0.27	< 0.001
	Anti-maspin	0.69(0.62–0.77)	35.56	86.67	2.67	0.74	0.22	< 0.001
	Anti-ANXA3	0.62(0.54–0.70)	26.67	91.11	3.00	0.80	0.18	0.005
	Anti-eEF2	0.62(0.54–0.70)	34.44	86.67	2.58	0.76	0.21	0.004

Sen Sensitivity, Sep Specificity, +LR Positive Likelihood Ratio, -LR Negative Likelihood Ratio, YI Youden Index

ISSN: 1471-2407